Other

Corus Pharma, Inc.

Neumedics

Iain W Duncan

Edward A Kesicki

Irina C Jacobson

Carl G Osborne

William D Schwieterman

Alan Bruce Montgomery

Peter Carbonaro

The present disclosure is directed to compositions and methods which utilize the tetracycline scaffold, preferably the scaffold of tetracycline or minocycline, and which significantly lack antibiotic activity. The compounds have neuroprotective attributes without interfering with the drugs capacity to pass through the blood brain barrier. These compounds have neuroprotective activity because of their inhibition of neuronal cell cycle progression. The compounds are characterized in part by a fifth ring joining positions 9 and 10.

Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits

A process for manufacturing bulk solutions and lyophilized pure &#x3b1;-aztreonam lysinate for large scale production of an inhalable aztreonam is disclosed, as is a pure &#x3b1;-aztreonam lysinate for inhalation. A dry powder or lyophilized pure &#x3b1;-aztreonam lysinate composition for inhalation is also disclosed.

Process for manufacturing bulk solutions and a lyophilized pure &#x3b1;-aztreonam lysinate

Growing community of inventors

Seattle, WA, United States of America

Iain W Duncan